About

They work to accelerate translation of innovative discoveries into therapeutics.

They are a leading-edge translational biotechnology company focused on developing personalized in-vitro and in-vivo modalities using stem cell / patient-derived tumors (PDX platforms) for various cancers. They enable the identification of personalized cancer care and screening of drug molecules for re-purposing towards cancer therapy using their PDX and organoid models.

They follow the 3 R's Principle – Replacement, Reduction and Refinement in case of experimental animal usage as an alternative. They like to replace animal experiments with invitro methods. They diligently try to find alternatives to use of animals in research. But when the usage of animals is needed they reduce the numbers and refine their practices.

They aim to help the medical oncologists and Pharma R&D take an informed decision in real-time, to treat their patients, or discover new therapeutics by creating stem cell or in vitro patient tumor-derived Organoids/Spheroids platform.